JP2022526624A - 骨及び関節の感染を治療及び予防する方法 - Google Patents

骨及び関節の感染を治療及び予防する方法 Download PDF

Info

Publication number
JP2022526624A
JP2022526624A JP2021559424A JP2021559424A JP2022526624A JP 2022526624 A JP2022526624 A JP 2022526624A JP 2021559424 A JP2021559424 A JP 2021559424A JP 2021559424 A JP2021559424 A JP 2021559424A JP 2022526624 A JP2022526624 A JP 2022526624A
Authority
JP
Japan
Prior art keywords
lysate
gram
seq
bone
antibiotics
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021559424A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022526624A5 (https=
Inventor
レイモンド シューフ
Original Assignee
コントラフェクト コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by コントラフェクト コーポレイション filed Critical コントラフェクト コーポレイション
Publication of JP2022526624A publication Critical patent/JP2022526624A/ja
Publication of JP2022526624A5 publication Critical patent/JP2022526624A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Surgery (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2021559424A 2019-04-11 2020-04-10 骨及び関節の感染を治療及び予防する方法 Pending JP2022526624A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962832754P 2019-04-11 2019-04-11
US62/832,754 2019-04-11
US201962849672P 2019-05-17 2019-05-17
US62/849,672 2019-05-17
US201962938812P 2019-11-21 2019-11-21
US62/938,812 2019-11-21
US202062964755P 2020-01-23 2020-01-23
US62/964,755 2020-01-23
PCT/US2020/027752 WO2020210691A1 (en) 2019-04-11 2020-04-10 Method of treating and preventing bone and joint infections

Publications (2)

Publication Number Publication Date
JP2022526624A true JP2022526624A (ja) 2022-05-25
JP2022526624A5 JP2022526624A5 (https=) 2023-04-03

Family

ID=72752118

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021559424A Pending JP2022526624A (ja) 2019-04-11 2020-04-10 骨及び関節の感染を治療及び予防する方法

Country Status (11)

Country Link
US (1) US20220193186A1 (https=)
EP (1) EP3980049A4 (https=)
JP (1) JP2022526624A (https=)
KR (1) KR20210151188A (https=)
CN (1) CN114025783A (https=)
AU (1) AU2020271116A1 (https=)
BR (1) BR112021019884A2 (https=)
CA (1) CA3136461A1 (https=)
IL (1) IL286994A (https=)
MX (1) MX2021012375A (https=)
WO (1) WO2020210691A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023081691A1 (en) * 2021-11-04 2023-05-11 Contrafect Corporation Method of treating and preventing bone and joint infections

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015521178A (ja) * 2012-05-09 2015-07-27 コントラフェクト コーポレイション バクテリオファージ溶解素によるバイオフィルムの防止、破壊および処置

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2833409A1 (en) * 2011-04-21 2012-10-26 The Rockefeller University Streptococcus bacteriophage lysins for detection and treatment of gram positive bacteria
KR20210121313A (ko) * 2012-05-09 2021-10-07 콘트라펙트 코포레이션 그람 양성 박테리아에 대한 박테리오파지 리신과 항생제의 병용물
KR20190004799A (ko) * 2016-05-12 2019-01-14 콘트라펙트 코포레이션 항균 폴리펩티드의 최소 억제 농도를 평가 및 탐지하기 위한 배지미량희석법
KR20200124724A (ko) * 2018-02-26 2020-11-03 콘트라펙트 코포레이션 변형된 PlySs2 리신 및 이의 용도
CN112867398A (zh) * 2018-06-22 2021-05-28 康特拉费克特公司 溶素及其衍生物使金黄色葡萄球菌和革兰氏阳性菌对抗生素重新敏感

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015521178A (ja) * 2012-05-09 2015-07-27 コントラフェクト コーポレイション バクテリオファージ溶解素によるバイオフィルムの防止、破壊および処置

Also Published As

Publication number Publication date
CA3136461A1 (en) 2020-10-15
WO2020210691A1 (en) 2020-10-15
AU2020271116A1 (en) 2021-11-11
BR112021019884A2 (pt) 2022-01-18
KR20210151188A (ko) 2021-12-13
IL286994A (en) 2021-12-01
EP3980049A4 (en) 2023-07-19
US20220193186A1 (en) 2022-06-23
EP3980049A1 (en) 2022-04-13
CN114025783A (zh) 2022-02-08
MX2021012375A (es) 2021-11-17

Similar Documents

Publication Publication Date Title
US20220362352A1 (en) Use of lysin to restore/augment antibacterial activity in the presence of pulmonary surfactant of antibiotics inhibited thereby
KR102310387B1 (ko) 그람 양성 박테리아에 대한 박테리오파지 리신과 항생제의 병용물
CN112368376A (zh) 溶素-抗微生物肽(amp)多肽构建体、溶素、其分离的编码多核苷酸及其用途
KR20210118980A (ko) 박테리오파지 리신을 이용한 생물막의 예방, 붕괴 및 치료
JP2024010053A (ja) シュードモナス・エルギノーサに対する殺菌活性を有する溶解素及びその誘導体の特定
Cudic et al. In vitro and in vivo activity of an antibacterial peptide analog against uropathogens
KR20010022237A (ko) 리소스타핀을 단독 또는 항생제와의 조합으로 포함하는포도상구균 감염 치료용 약제학적 조성물
JP2021527699A (ja) 溶解素及びその誘導体がスタフィロコッカス・アウレウス及びグラム陽性細菌を抗生物質に再感作する
JP2021513865A (ja) 修飾ＰｌｙＳｓ２溶解素及びその使用
US20210330738A1 (en) Antimicrobial, bacteriophage-derived polypeptides and their use against gram-negative bacteria
JP2022526624A (ja) 骨及び関節の感染を治療及び予防する方法
US20220160842A1 (en) Method of treating infective endocarditis
JP2022526978A (ja) ヒト血清の存在下でシュードモナス・エルギノーサに対する殺菌活性を有する溶解素及びその誘導体
WO2023081691A9 (en) Method of treating and preventing bone and joint infections
RU2813626C1 (ru) Модифицированный эндолизин и антибактериальные композиции на его основе для лечения инфекций, вызванных бактериями Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, Escherichia coli
Elst Clinical implementation of endolysins targeting gram-positive bacteria points toward a combination strategy with standard-of-care antibiotics: a selective review
JP2023526386A (ja) グラム陽性細菌に対して使用される修飾ＰｌｙＳｓ２溶解素及び抗生物質の組合せ
RU2807688C9 (ru) Идентификация лизинов и их производных, обладающих антибактериальной активностью против pseudomonas aeruginosa
RU2807688C2 (ru) Идентификация лизинов и их производных, обладающих антибактериальной активностью против pseudomonas aeruginosa
Linden An investigation on a bacteriophage endolysin possessing antimicrobial activity against antibiotic-resistant Staphylococcus aureus
Röhrig Application of Bacteriophage Proteins in Medicine and Foods
CN115209912A (zh) 肽组合物及其使用方法
EP3724330A1 (en) Compositions and methods comprising lysin plycp025 and derivatives thereof
Vander Elst Clinical implementation of Gram-positive endolysins points towards a combination strategy with standard-of-care antibiotics: a selective review

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230324

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230324

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240326

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241022